scholarly journals CLINICAL AND ECONOMIC EVALUATION OF CHRONIC DISEASE TREATMENT: A DISCREPANCY BETWEEN THE TRADITIONAL PHARMACOECONOMIC AND SOCIO-ECONOMIC ANALYSES

Author(s):  
O. V. Zhukova ◽  
S. V. Kononova
2014 ◽  
Vol 19 (3) ◽  
pp. 716-726 ◽  
Author(s):  
Ellen A. Lipstein ◽  
Cassandra M. Dodds ◽  
Daniel J. Lovell ◽  
Lee A. Denson ◽  
Maria T. Britto

Biomolecules ◽  
2020 ◽  
Vol 10 (12) ◽  
pp. 1674
Author(s):  
Hang Fai Kwok

In the last decade, natural-derived/-based biomolecules have continuously played an important role in novel drug discovery (as a prototype drug template) for potential chronic disease treatment [...]


2010 ◽  
Vol 5 (4) ◽  
pp. 411-435 ◽  
Author(s):  
David H. Howard ◽  
Kenneth E. Thorpe ◽  
Susan H. Busch

AbstractThe proportion of the population treated for major medical conditions, including diabetes, cancer and mental illness, increased rapidly during the 1990s. We document the magnitude of these increases and use a model of prevalence to identify three potential causes: increased clinical incidence of disease, longer survival times among persons with chronic illnesses and increased detection. We present a series of analyses to evaluate the contribution of each factor. We find that increases in obesity explain a large proportion of the increase in treatment rates for conditions closely linked to obesity (e.g. diabetes). We provide some evidence that increases in treated prevalence unexplained by changes in the underlying clinical incidence of disease are driven by increased detection and treatment of patients with ‘subclinical’ illness.


2015 ◽  
Vol 35 (6) ◽  
pp. 703-713 ◽  
Author(s):  
Ellen A. Lipstein ◽  
Maria T. Britto

Author(s):  
Daniel Chisholm ◽  
Paul McCrone

This chapter examines the interface between psychiatric epidemiology and health economics, particularly in relation to mental health service evaluation. We discuss the issues inherent in conducting an economic evaluation and conclude with a summary of the applications of economic analyses.


BMJ Open ◽  
2017 ◽  
Vol 7 (8) ◽  
pp. e017089 ◽  
Author(s):  
Alexander W Carter ◽  
Rishi Mandavia ◽  
Erik Mayer ◽  
Joachim Marti ◽  
Elias Mossialos ◽  
...  

IntroductionRecent avoidable failures in patient care highlight the ongoing need for evidence to support improvements in patient safety. According to the most recent reviews, there is a dearth of economic evidence related to patient safety. These reviews characterise an evidence gap in terms of the scope and quality of evidence available to support resource allocation decisions. This protocol is designed to update and improve on the reviews previously conducted to determine the extent of methodological progress in economic analyses in patient safety.Methods and analysisA broad search strategy with two core themes for original research (excluding opinion pieces and systematic reviews) in ‘patient safety’ and ‘economic analyses’ has been developed. Medline, Econlit and National Health Service Economic Evaluation Database bibliographic databases will be searched from January 2007 using a combination of medical subject headings terms and research-derived search terms (see table 1). The method is informed by previous reviews on this topic, published in 2012. Screening, risk of bias assessment (using the Cochrane collaboration tool) and economic evaluation quality assessment (using the Drummond checklist) will be conducted by two independent reviewers, with arbitration by a third reviewer as needed. Studies with a low risk of bias will be assessed using the Drummond checklist. High-quality economic evaluations are those that score >20/35. A qualitative synthesis of evidence will be performed using a data collection tool to capture the study design(s) employed, population(s), setting(s), disease area(s), intervention(s) and outcome(s) studied. Methodological quality scores will be compared with previous reviews where possible. Effect size(s) and estimate uncertainty will be captured and used in a quantitative synthesis of high-quality evidence, where possible.Ethics and disseminationFormal ethical approval is not required as primary data will not be collected. The results will be disseminated through a peer-reviewed publication, presentations and social media.Trial registration numberCRD42017057853.


2013 ◽  
Vol 53 (2) ◽  
pp. 253-259 ◽  
Author(s):  
Ellen A. Lipstein ◽  
Kelly A. Muething ◽  
Cassandra M. Dodds ◽  
Maria T. Britto

2014 ◽  
Vol 24 (5) ◽  
pp. 489-496 ◽  
Author(s):  
Kerri-Anne Mullen ◽  
Douglas Coyle ◽  
Douglas Manuel ◽  
Hai V Nguyen ◽  
Ba’ Pham ◽  
...  

2013 ◽  
Vol 52 (2) ◽  
pp. S111
Author(s):  
Ellen A. Lipstein ◽  
Kelly A. Muething ◽  
Cassandra M. Dodds ◽  
Maria T. Britto

Sign in / Sign up

Export Citation Format

Share Document